Latest News on Mankind Pharma
The PHD Chamber of Commerce and Industry’s board has extended a warm welcome to Juneja’s presidency, as well as the leadership of Gupta and Singhania.
The PHD Chamber of Commerce and Industry (PHDCCI) has announced its new leadership team, with Rajeev Juneja taking over as President, succeeding Hemant Jain. Juneja, who is also the Vice Chairman and Managing Director of Mankind Pharma Ltd., brings extensive experience in the pharmaceutical industry to the position. He has outlined his vision for the Chamber, which includes building stronger industry linkages, promoting innovation, and contributing to the vision of Viksit Bharat @2047 through collaborative growth and self-reliance.
Anil Gupta, Chairman and Managing Director of KEI Industries Ltd., has been appointed as Senior Vice President, while Sanjay Singhania, Managing Director and CEO of Epack Prefab Technologies Limited, has taken over as Vice President. Both Gupta and Singhania have expressed their delight at being part of the new leadership team and have pledged to work closely with Juneja and the Chamber’s members to drive impactful initiatives for industry and society.
Hemant Jain, the Immediate Former President, reflected on his tenure, stating that serving as President of PHDCCI has been a deeply fulfilling experience. He expressed confidence that the Chamber will continue to expand its impact under the new leadership. Dr. Ranjeet Mehta, CEO and Secretary General of PHDCCI, welcomed the new team, stating that their combined vision, strategic insight, and commitment to excellence will help the Chamber further strengthen its role as a catalyst for national growth and global competitiveness.
The new leadership team is expected to build on the Chamber’s existing strengths and take it to newer heights. With their extensive experience and expertise, they are well-equipped to drive growth, innovation, and self-reliance in various industries. The PHDCCI is a prominent industry body that plays a crucial role in promoting trade, commerce, and industry in India. The appointment of the new leadership team is expected to further enhance the Chamber’s ability to support the growth and development of Indian businesses.
The vision of the new President, Rajeev Juneja, is aligned with the government’s vision of Viksit Bharat @2047, which aims to make India a developed country by 2047. The Chamber’s focus on building stronger industry linkages, promoting innovation, and contributing to the vision of Viksit Bharat @2047 is expected to have a positive impact on the Indian economy. The new leadership team is committed to working closely with the government, industry stakeholders, and members to drive growth and development in various sectors.
Myra Kapoor, an AI model, has been unveiled as the new brand ambassador for Manforce Condoms.
In a groundbreaking move, Manforce Condoms has introduced an AI model, Myra Kapoor, as its new brand ambassador. This innovative approach aims to encourage open and honest conversations about intimacy. The AI ambassador was launched through a television commercial, which marks a new frontier in brand communication. Created by Grapes Worldwide, Myra Kapoor was developed based on insights from a management institute study, with the goal of portraying the emotions of people.
According to Rajeev Juneja, Vice Chairman & Managing Director of Mankind Pharma, the parent company of Manforce Condoms, the introduction of Myra Kapoor represents a significant milestone in the brand’s communication strategy. Juneja expressed excitement about pioneering this new approach, stating that AI technology offers incredible opportunities for creative storytelling. He emphasized that Myra embodies the company’s commitment to innovation and pushing boundaries.
The appointment of an AI brand ambassador provides Manforce Condoms with limitless creative possibilities. With Myra, the brand can create dynamic and responsive campaigns that seamlessly align with its vision. This approach allows for a more engaging and interactive way to connect with consumers, which is particularly important when discussing sensitive topics like intimacy.
The launch of Myra Kapoor is part of Manforce Condoms’ monsoon campaign, which marks the beginning of a transformative journey in the brand’s communication strategy. By leveraging AI technology, the brand aims to create a more open and honest dialogue about intimacy, which is essential for building strong relationships and promoting healthy lifestyles. With Myra Kapoor as its brand ambassador, Manforce Condoms is poised to revolutionize the way it engages with consumers and promotes its products.
Overall, the introduction of Myra Kapoor as Manforce Condoms’ AI brand ambassador represents a bold and innovative approach to brand communication. By embracing AI technology, the brand is pushing the boundaries of creative storytelling and engagement, and is likely to set a new standard for the industry. As Juneja noted, this is just the beginning of a transformative journey, and it will be exciting to see how Manforce Condoms continues to evolve and innovate in the future.
Delhi High Court Provides Temporary Protection for ‘Kind’ Trademark Family in Ongoing Legal Dispute
The Delhi High Court has granted an ex-parte ad-interim injunction in favor of Mankind Pharma Limited, a leading pharmaceutical company in India, to protect its well-established “Kind” family of marks. The court’s decision was made in response to the defendant’s use of deceptively similar marks, such as “DICKIND”, “LONOKIND”, “FENKIND”, and “CHIMOKIND”, in relation to pharmaceutical products. The plaintiff argued that Mankind Pharma has been using its “Kind” family of trademarks since 1995, establishing extensive goodwill, reputation, and consumer trust in the pharmaceutical industry.
The court observed that the similarity between the plaintiff’s and defendant’s marks created a case of “triple identity”, where the marks were identical, the product category was the same, and the trade channels and consumer base overlapped. The court held that the defendant’s conduct was prima facie dishonest, aimed at riding on the reputation of Mankind Pharma, and granted interim relief till the next hearing scheduled for January 28, 2026.
The plaintiff had argued that the use of identical or deceptively similar marks by the defendant amounts to infringement under the Trade Marks Act, 1999, and also constitutes passing off, as it is likely to deceive consumers and erode trust in the plaintiff’s products. The company stressed that the defendant’s use of marks such as “DICKIND”, “LONOKIND”, “FENKIND”, and “CHIMOKIND” is not only visually and phonetically similar to its established marks but also creates a likelihood of confusion, especially since both parties operate in the same product category and target the same consumer base.
The court applied the “triple identity” test and held that the defendant’s adoption of the impugned marks was prima facie dishonest, amounting to an attempt to ride on the goodwill and reputation of the plaintiff. The court emphasized that the pharmaceutical sector requires heightened scrutiny because of the serious implications of confusion in drug names. The court restrained the defendants from using the impugned marks till the next date of hearing, January 28, 2026, and noted that the balance of convenience lay in favor of the plaintiff, as denial of relief would cause irreparable harm to its goodwill and reputation.
The defendant was not represented during the hearing, but it is likely that they could have argued that the marks adopted by them were distinct, descriptive, or coined independently without an intent to infringe upon the plaintiff’s trademarks. They may have also argued that the plaintiff cannot claim exclusivity over the suffix “Kind”, as it is used by several players in the pharmaceutical industry. However, the court’s decision suggests that the plaintiff’s “Kind” family of marks is entitled to a higher level of protection, given its long and continuous use and the reputation it enjoys in the pharmaceutical sector.
The ruling is significant as it highlights the importance of protecting intellectual property rights in the pharmaceutical industry, where confusion in drug names can have serious consequences for patients. The court’s decision is also a testament to the strength of Mankind Pharma’s “Kind” family of marks, which has been established over three decades of consistent use and has become a well-recognized brand in the pharmaceutical industry.
Delhi High Court issues interim injunction to safeguard Mankind Pharma’s ‘KIND’ trademark.
The Delhi High Court has granted an interim injunction to Mankind Pharma Limited, restraining the defendants from using trademarks that are deceptively similar to Mankind’s trademarks, including ‘KIND’, ‘FENDIKIND’, ‘ZENKIND’, and ‘DIZIKIND’. The court held that the defendants’ products, such as ‘FENKIND’, ‘DICKIND’, ‘LONOKIND’, and ‘CHIMOKIND’, were identical or deceptively similar to Mankind’s products and amounted to trademark infringement.
Mankind Pharma Limited is a well-known pharmaceutical company that has acquired tremendous goodwill and reputation in India and globally. The company is the registered proprietor of several trademarks, including ‘FENDIKIND’, ‘ZENKIND’, and ‘DIZIKIND’, and its trademarks ‘MANKIND’ and ‘KIND’ have been declared as well-known trademarks by the Registrar of Trade Marks.
The court noted that Mankind had established long and continuous use of its trademark, which had been registered since 1995. The use of Mankind’s trademark by the defendant was seen as an attempt to ride on the established goodwill and reputation of Mankind, and was thus a prima facie dishonest attempt to confuse the market.
The court opined that Mankind, being the prior user and adopter of the mark ‘KIND’, was entitled to protection. The court held that Mankind had made out a prima facie case for grant of an ex-parte ad-interim injunction, and that the balance of convenience was in favor of Mankind and against the defendant.
As a result, the court restrained the defendant from manufacturing, selling, or advertising products under the marks ‘DICKIND’, ‘LONOKIND’, ‘FENKIND’, and ‘CHIMOKIND’, or any other trademark that may be identical or deceptively similar to Mankind’s trademarks. The matter has been listed for further hearing on January 28, 2026.
The advocates who appeared in this case were Ankur Sangal, Ankit Arvind, Nidhi Pathak, and Rishab Rao for the plaintiff, Mankind Pharma Limited. The court’s decision is a significant victory for Mankind Pharma Limited, and underscores the importance of protecting intellectual property rights in the pharmaceutical industry.
Delhi High Court blocks use of ‘FENKIND’ and similar marks to safeguard Mankind Pharma’s ‘KIND’ trademark.
The Delhi High Court has recently ruled in favor of Mankind Pharma, a prominent Indian pharmaceutical company, in a trademark infringement case. The court has restrained the use of the mark ‘FENKIND’ and any other similar marks that may infringe upon Mankind Pharma’s ‘KIND’ trademark family. This decision is a significant victory for Mankind Pharma, as it protects the company’s intellectual property rights and prevents potential confusion among consumers.
Mankind Pharma had filed a lawsuit against another pharmaceutical company, which was using the mark ‘FENKIND’ for one of its products. The plaintiff argued that the defendant’s use of the mark ‘FENKIND’ was likely to cause confusion among consumers, as it was similar to Mankind Pharma’s ‘KIND’ trademark family. The court agreed with Mankind Pharma’s argument and held that the defendant’s use of the mark ‘FENKIND’ did indeed infringe upon the plaintiff’s trademark rights.
The court’s decision is based on the principles of trademark law, which aim to protect consumers from confusion and deception. The use of a similar mark can lead to confusion among consumers, who may mistakenly believe that the products are related or come from the same source. In this case, the court found that the defendant’s use of the mark ‘FENKIND’ was likely to cause confusion among consumers, as it was similar to Mankind Pharma’s well-known ‘KIND’ trademark family.
The ‘KIND’ trademark family is a valuable asset for Mankind Pharma, and the company has invested significant resources in building and promoting its brand. The court’s decision recognizes the importance of protecting intellectual property rights and prevents other companies from profiting from Mankind Pharma’s reputation and goodwill.
The Delhi High Court’s ruling is a significant development in the field of trademark law in India. It highlights the importance of protecting intellectual property rights and preventing trademark infringement. The decision is also a testament to the Indian judiciary’s commitment to upholding the principles of trademark law and protecting the rights of businesses and consumers alike.
In conclusion, the Delhi High Court’s decision to restrain the use of the mark ‘FENKIND’ and similar marks is a significant victory for Mankind Pharma and a important development in the field of trademark law in India. The decision protects Mankind Pharma’s intellectual property rights, prevents confusion among consumers, and upholds the principles of trademark law. It also serves as a reminder to businesses of the importance of respecting the intellectual property rights of others and the need to conduct thorough trademark searches before launching new products or services.
Stock Market Updates for Mankind Pharma
Recent Updates
The Delhi ITAT has cancelled a discretionary disallowance of Rs 14.98 crore related to travel expenses for Mankind Pharma.
The Income Tax Appellate Tribunal (ITAT) has ruled in favor of Mankind Pharma, allowing the company to claim a total travelling and conveyance expenditure of Rs. 18,73,43,027 for the year. The company, engaged in trading pharmaceutical products, had claimed this expense as part of its business operations, primarily for door-to-door marketing and sales activities. The Assessing Officer (AO) had initially disallowed approximately 80% of the total expenses, citing a lack of supporting documentation.
However, the Commissioner of Income Tax (Appeals) [CIT(A)] reduced the disallowance to 20% after reviewing the company’s submissions and policy framework for reimbursements. The CIT(A) observed that the company’s policy was based on commercial expediency and aimed to simplify the process of reimbursing employees for legitimate business expenses.
The ITAT, comprising S. Rifaur Rahman and Shri Anubhav Sharma, examined the company’s business model and noted that the medical representatives (MRs) travel extensively to procure orders and make product presentations. The tribunal highlighted the company’s policy, which reimbursed travel at Rs. 2.80 per km and provided daily allowances depending on designation and travel location. The reimbursement claims underwent multiple levels of verification by the management before payment.
The ITAT relied on precedents, including CIT vs. Larsen & Toubro Ltd. and Hero MotoCorp Ltd. vs. ACIT, which held that expenses reimbursed on the basis of company policy and employee certification could not be disallowed solely for lack of vouchers. The tribunal observed that even if employees were reimbursed higher than the actual expenditure, the higher reimbursement on a bonafide basis constituted an expenditure incurred for the purpose of business and could not be considered personal or non-business expenditure.
The ITAT concluded that the AO’s ad-hoc disallowance of 80% of travelling and conveyance expenses was unjustified and allowed the assessee’s appeal while dismissing the Revenue’s appeal. The order was pronounced in open court on 27th August 2025, holding that the expenses of Rs. 18,73,43,027 were eligible as business deductions. This ruling reinforces the principle of consistent treatment, as similar reimbursement policies had been accepted in prior assessment years without dispute.
Prominent pharmaceutical companies such as Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, and Torrent Pharma are navigating the complexities of the pharma value chain.
The pharmaceutical industry is complex, with various segments such as innovator products, generics, branded generics, and API. Indian companies are making headway globally, and understanding the industry’s intricacies is crucial for those seeking opportunities. Innovator companies undertake significant risks, with only 8 out of 100 molecules crossing the finish line, and patent protection is the incentive for undertaking this risk. Roche, a leading innovator, reported a 30% PAT margin in FY24, with R&D expenses at 20% of sales.
Indian pharma is sustained by generics, but companies like Sun Pharma and Glenmark Pharma are making modest beginnings in innovation. Sun Pharma’s innovative medicine segment has 11 products, including Ilumya, which reported sales of $680 million in FY25. Glenmark Pharma’s Ichnos Glenmark Innovation (IGI) recently entered a licensing agreement with AbbVie for its ISB 2001, receiving $700 million in milestone payments.
The generics business is dependent on the level of competition, with prices declining sharply as the number of competitors increases. Branded generics, however, offer higher value, with companies like Mankind Pharma and Torrent Pharma generating significant revenues from their branded portfolios. Complex generics, such as Lupin’s generic Spiriva, hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
Biosimilars are a growing segment, with companies like Biocon developing portfolios. The biosimilar approval process involves clinical trials, increasing the cost of development to $200-300 million. CRDMO (contract research and development and manufacturing outsourcing) is another emerging segment, with companies like Divi’s Labs and Anthem Biosciences securing a portion of the innovators’ drug development process.
The API business is largely commoditized, with prices dependent on tonnage. However, high-potent APIs and complex manufacturing processes can fetch higher margins. India has focused on API development with its PLI schemes, and companies like Aurobindo Pharma are establishing API facilities.
For investors, a strong branded generic base supplemented by a wide innovator portfolio is essential for trail-blazing growth. Complex generics and CRDMO are emerging sectors, with China+1 and the US Biosecure Act providing tailwinds. The right mix of business segments and prospects is crucial for growth, and understanding the industry’s intricacies is essential for those seeking opportunities in the pharmaceutical sector.
Key takeaways include:
* Innovator companies undertake significant risks, but patent protection provides an incentive.
* Indian pharma is sustained by generics, but companies are making modest beginnings in innovation.
* Branded generics offer higher value, with companies generating significant revenues from their branded portfolios.
* Complex generics hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
* Biosimilars are a growing segment, with companies developing portfolios.
* CRDMO is an emerging segment, with companies securing a portion of the innovators’ drug development process.
* The API business is largely commoditized, but high-potent APIs and complex manufacturing processes can fetch higher margins.
Sun Pharma and Lupin are developing an anti-obesity oral medication to reduce costs and cater to those hesitant about injections.
The Indian pharmaceutical companies, Sun Pharma and Lupin, are developing oral semaglutide pills to address obesity and injection aversion. Currently, leading anti-obesity drugs like Mounjaro and Wegovy are available in injectable form, limiting accessibility and patient comfort. The Drugs Controller General of India (DCGI) has given Sun Pharma permission for a large-scale clinical trial to test its semaglutide tablets, while Lupin has received the green light for its bioequivalence study.
Obesity is becoming a significant public health challenge in India, with a projected 450 million overweight and obese adults by 2050. Experts believe that the injectable form of semaglutide is more effective for weight loss, but the oral variant could improve accessibility and patient comfort. Other Indian companies, such as Dr. Reddy’s Laboratories Ltd, Cipla Ltd, and Mankind Pharma, are also developing generic versions of semaglutide.
The development of these anti-obesity drugs is significant, and experts urge strict medical supervision and caution against misuse. Dr. Balram Bhargava, former director general of the Indian Council of Medical Research (ICMR), said that these drugs are “wonder drugs and novel inventions” but should be used under strict medical supervision. He added that irrational use of these drugs could have serious consequences and that they are suitable as a second line of treatment for individuals who are obese and diabetic.
The key takeaways from this development are:
1. Sun Pharma and Lupin are developing oral semaglutide pills to address obesity and injection aversion.
2. Regulatory approvals have been granted for Phase III trials and bioequivalence studies.
3. India faces an obesity burden of 450 million adults by 2050.
4. Experts urge strict medical supervision and caution against misuse.
5. Generic versions may flood the market next year, reshaping affordability and access.
Overall, the development of oral semaglutide pills and the upcoming availability of generic versions could significantly impact the treatment of obesity in India. However, it is crucial to ensure that these drugs are used responsibly and under strict medical supervision to avoid misuse and potential consequences.
Mankind Pharma emerges victorious in PETKIND trademark dispute, court directs publication of advertisement in journal within 60-day timeframe
Mankind Pharma has recently emerged victorious in a trademark battle involving the PETKIND trademark. The court has ruled in favor of Mankind Pharma, ordering the opposing party to publish a journal advertisement within a period of two months.
The specifics of the trademark dispute and the court’s decision have not been detailed, but it can be inferred that Mankind Pharma successfully demonstrated its rights to the PETKIND trademark. This outcome highlights the importance of trademark protection and the measures companies must take to safeguard their intellectual property.
The court’s order for the opposing party to publish a journal advertisement acknowledging Mankind Pharma’s victory is a significant step. This move serves as a public declaration of the court’s decision, helping to inform the public and the business community about the outcome of the dispute. By doing so, it reinforces the legitimacy of Mankind Pharma’s claim to the PETKIND trademark and helps prevent potential confusion or misuse of the trademark by other parties.
The use of journal advertisements as a means of disseminating information about court decisions is not uncommon. It provides a formal and widely accessible platform for announcing the outcome of legal disputes, ensuring transparency and awareness among stakeholders. In this case, the journal advertisement will likely outline the key points of the court’s decision, reiterating Mankind Pharma’s rights to the PETKIND trademark and cautioning others against infringing upon these rights.
Mankind Pharma’s success in this trademark battle underscores the company’s commitment to protecting its intellectual property and maintaining its competitive edge in the market. The pharmaceutical industry is highly competitive, and trademarks play a crucial role in distinguishing one company’s products from another. By vigorously defending its trademarks, Mankind Pharma demonstrates its dedication to upholding its brand identity and reputation.
The outcome of this dispute also serves as a reminder to businesses of the importance of conducting thorough trademark searches and ensuring that their branding does not infringe upon existing trademarks. This proactive approach helps prevent costly legal battles and potential damage to a company’s reputation. As the pharmaceutical landscape continues to evolve, the ability to protect and enforce intellectual property rights will remain a vital aspect of a company’s overall strategy.
Nimulid forms a powerful alliance with the Patna Pirates for the upcoming Season 12 of the Pro Kabaddi League.
Mankind Pharma’s Nimulid Strong has partnered with the Patna Pirates as the Official Pain Relief Partner for Pro Kabaddi League Season 12. This partnership aligns the brand’s powerful pain relief formula with the intense physical demands of kabaddi, a sport known for sudden pulls, rapid twists, and heavy tackles that strain the neck and body. Nimulid Strong stands out in the topical pain relief market with a 2.32% diclofenac concentration, double the standard 1.16% found in most products.
The brand’s formula provides relief in just 2 minutes, making it ideal for players who need instant recovery. Nimulid Strong is available in gel and spray formats, targeting neck pain from intense kabaddi movements. The gel format provides deep-penetrating, long-lasting relief, while the spray format offers on-the-go convenience. In its first year, the brand has sold around 20 lakh gel units and 10 lakh spray units, demonstrating its remarkable market performance.
Mr. Joy Chatterjee, Vice President of Sales and Marketing at Mankind Pharma, emphasized that the partnership celebrates India’s indigenous sport while supporting athletes and everyday warriors who push through pain. The company plans to expand the brand’s offerings with innovative formats like balms, roll-ons, and tablets, reinforcing its commitment to effective and accessible pain relief solutions.
The topical pain relief market in India is valued at over ₹5,000 crore, and Nimulid Strong’s unique formula and quick action have positioned it as a leader in this market. The partnership with the Patna Pirates is a strategic move to increase brand awareness and reach a wider audience. With its powerful pain relief formula and convenient formats, Nimulid Strong is well-positioned to become a go-to solution for individuals seeking quick and effective pain relief.
The collaboration between Mankind Pharma and the Patna Pirates is a win-win for both parties, as it promotes the brand’s products while supporting the team’s athletes and celebrating India’s indigenous sport. As the Pro Kabaddi League Season 12 progresses, Nimulid Strong’s partnership with the Patna Pirates is likely to increase brand visibility and drive sales, further solidifying its position in the topical pain relief market.
Mankind Pharma Limited receives counsel from Luthra and Luthra, EPAM Law Offices for establishing its Russian subsidiary.
Mankind Pharma, an Indian pharmaceutical company, has successfully incorporated a subsidiary in Russia. This process was facilitated by Luthra and Luthra Law Offices India, which provided comprehensive legal advice and guidance. The law firm played a crucial role in structuring the subsidiary, ensuring compliance with Russian regulations, and navigating the complexities of international sanctions.
Luthra and Luthra Law Offices India coordinated with Russian counsel to ensure a seamless incorporation process. The firm’s expertise in cross-border transactions and regulatory matters was instrumental in overcoming the challenges posed by international sanctions. The team advised Mankind Pharma on the optimal structure for the subsidiary, taking into account the prevailing regulatory landscape.
The transaction was led by Pradnesh Warke, a partner at Luthra and Luthra Law Offices India, who brought his expertise in corporate law and cross-border transactions to the table. He was supported by a team of experienced lawyers, including Ravi Raj Shekhar, a senior associate, and associates Devashree Kulkarni and Tanay Jha. Together, they worked closely with Mankind Pharma to ensure that all documentation and regulatory requirements were met, facilitating a smooth incorporation process.
The incorporation of a subsidiary in Russia is a significant milestone for Mankind Pharma, marking its expansion into a new market. The company’s decision to establish a presence in Russia reflects its commitment to growing its global footprint and increasing its access to new markets. Luthra and Luthra Law Offices India’s role in this process demonstrates the firm’s capabilities in handling complex cross-border transactions and its ability to navigate challenging regulatory environments.
The success of this transaction is a testament to the strong partnership between Mankind Pharma and Luthra and Luthra Law Offices India. The law firm’s expertise and guidance were essential in ensuring that the incorporation process was completed efficiently and effectively, despite the complexities posed by international sanctions. As Mankind Pharma continues to expand its global presence, the company can rely on Luthra and Luthra Law Offices India to provide expert legal advice and support.
Pharma’s quest for expansion: Reaching out to the consumer’s doorstep
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and Johnson, and Sanofi separating their consumer healthcare divisions. The rationale behind this strategy is to create a separate entity that can operate with a more agile and fast-moving consumer goods (FMCG) mindset, allowing for more focused marketing and advertising efforts.
According to Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, the company’s objective was to create a separate division for its over-the-counter (OTC) brands, which require a different environment, culture, and talent compared to prescription brands. The company had previously run its OTC business like its prescription business, but found that it was not effective. Juneja explains that some prescription brands can be transitioned to the consumer healthcare business within the regulatory framework, but everything should be different, including management, to stay focused and agile.
Subhakanta Bal, Managing Director and Head of Healthcare and Consumer at Rothschild & Co, notes that there are commonalities between consumer healthcare and the core prescription-driven business, but also differences. For example, consumer healthcare requires a more FMCG-like mindset, with a focus on marketing and advertising to drive sales. Bal observes that pharma companies often bring in FMCG veterans to run their consumer healthcare divisions, and that a separate entity can be more “fit for purpose”.
The pursuit of growth is the key reason behind the consumer healthcare demerging trend, according to Vishal Manchanda, Senior Vice-President at Systematix Group. Pharma companies are developing a second platform for growth, given the challenges in the domestic branded business and global uncertainties. However, it’s not an easy task, with intense competition from store-owned brands and pressure on prices.
The demerging of consumer healthcare businesses is expected to lead to better value realization, potentially through listing, as FMCG businesses in India trade at a higher value than domestic formulation businesses. Internationally, big pharma companies have separated or exited consumer healthcare to focus on innovation, but in India, the trend is driven by the need for right managerial talent, marketing, and advertising to ensure success. As the Indian pharmaceutical industry continues to evolve, the demerging of consumer healthcare businesses is likely to be a key strategy for growth and expansion.
Burn Pain Treatment Industry: Research, Therapies, and Key Players Including Johnson & Johnson, Mankind Pharma, Perrigo Company, Pfizer, Smith & Nephew, Sun Pharmaceutical, and Trio Li.
The burn pain market is a growing industry that is expected to expand due to the increasing incidence of burn injuries worldwide. According to DelveInsight, the market is driven by the rising demand for effective pain management therapies for burn patients. Burn pain is a complex and debilitating condition that can have a significant impact on a patient’s quality of life. The market is witnessing the emergence of new therapies and treatments that aim to provide relief to patients suffering from burn pain.
The epidemiology of burn pain is a significant concern, with millions of people suffering from burn injuries every year. The majority of burn injuries are minor, but a significant proportion require medical attention. The global burn pain market is expected to grow due to the increasing incidence of burn injuries, particularly in developing countries where access to healthcare is limited.
Several companies are actively involved in the development of burn pain therapies, including Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, and Trio Life Sciences. These companies are investing heavily in research and development to create innovative treatments for burn pain. For example, Johnson & Johnson is developing a new topical cream for the treatment of burn pain, while Pfizer Inc. is working on a novel oral medication.
The current treatment landscape for burn pain is dominated by analgesics, such as morphine and fentanyl, which are often ineffective in managing severe burn pain. However, new therapies are emerging, including topical creams, dressings, and other innovative treatments. For instance, Mankind Pharma has developed a new dressing that helps to reduce pain and promote wound healing.
The burn pain market is expected to grow significantly over the next few years, driven by the increasing demand for effective pain management therapies. The market is also witnessing the emergence of new companies, such as Trio Life Sciences, which is developing a novel burn pain treatment. Sun Pharmaceutical Industries Ltd is also investing heavily in research and development to create innovative treatments for burn pain.
In conclusion, the burn pain market is a growing industry that is expected to expand due to the increasing incidence of burn injuries worldwide. The market is driven by the rising demand for effective pain management therapies, and several companies are actively involved in the development of new treatments. The current treatment landscape is dominated by analgesics, but new therapies are emerging, including topical creams, dressings, and other innovative treatments. As the market continues to grow, it is expected to provide relief to millions of patients suffering from burn pain worldwide.
Lupin Splits Off Its Consumer Healthcare Business to Form Independent Company
Lupin, a leading pharmaceutical company, has created a new subsidiary called LupinLife Consumer Healthcare Ltd to house its consumer healthcare business. This move is in line with a growing trend among pharmaceutical companies, both in India and globally, to separate their consumer health operations from their prescription drug businesses. The goal is to better target the rapidly expanding self-care market in India. Anil Kaushal will lead the new subsidiary as CEO, bringing strategic focus and agility to Lupin’s consumer health portfolio.
The separation of the consumer healthcare business from the prescription drug business allows for more targeted investments and a dedicated approach to building strong consumer brands in the over-the-counter (OTC) space. Lupin’s OTC consumer healthcare business contributed ₹148 crore to the company’s total standalone revenue of ₹14,666 crore in FY24. The new subsidiary has a strong portfolio of scientifically formulated brands, including Softovac, Beplex Forte, Corcium, and Aptivate, which are positioned to leverage the rising demand for preventive healthcare and wellness in India.
The pharmaceutical sector is witnessing a trend of spinning off consumer health units, as companies recognize the need for separate business models to cater to prescription drugs and OTC healthcare products. This allows companies to streamline operations and adopt more FMCG-style promotion strategies tailored for consumer health products, while maintaining focus on their traditional pharma businesses. Companies such as Cipla, Glenmark, Mankind Pharma, and Sanofi have already adopted similar strategies.
The formation of LupinLife Consumer Healthcare Ltd reflects the company’s long-term vision of adapting to evolving healthcare needs and market dynamics in India. With this move, Lupin joins a broader industry shift that seeks to unlock value and accelerate growth in two distinct but complementary healthcare markets – prescription pharmaceuticals and consumer wellness products. The company’s move is expected to enable it to sharpen its focus on prescription drugs while allowing the OTC arm to thrive independently in a fast-growing and competitive consumer healthcare market.
Rajkummar Rao appointed as the Brand Ambassador for Nimulid Strong by Mankind Pharma
Mankind Pharma, India’s fourth-largest pharmaceutical company, has appointed Rajkummar Rao as the brand ambassador for its flagship product, Nimulid Strong Pain Relief Gel & Spray. This move aims to strengthen the company’s position in the topical pain relief segment. Nimulid Strong is positioned as the “Neck Pain Specialist” due to its powerful 2X Diclofenac formulation, which delivers rapid relief in just two minutes.
The partnership between Mankind Pharma and Rajkummar Rao aligns with the brand’s promise of effective, localized relief and the actor’s relatable persona. Joy Chatterjee, Vice President of Sales and Marketing at Mankind Pharma, expressed excitement about the collaboration, stating that Rajkummar’s authenticity and craft resonate deeply with the audience. Rajkummar Rao, known for his acclaimed performances in various films, shared his enthusiasm about endorsing Nimulid Strong, citing its promise of quick relief for neck pain as a game-changer.
Nimulid Strong has already made a strong debut in the topical pain relief market, valued at ₹5,000 crore, with over ₹15 crore in sales and approximately 30 lakh units sold in its first year. The product features a potent 2.32% Diclofenac formulation, delivering faster and deeper relief from neck pain, stiffness, and inflammation. Available in gel and spray formats, Nimulid Strong offers long-lasting and on-the-go solutions tailored for today’s digitally fatigued and posture-stressed generation.
Mankind Pharma plans to expand the product line to include balms, roll-ons, and tablets, with a focus on innovation and accessibility. The company is committed to addressing modern pain challenges such as tech neck, work-from-home strain, and sedentary fatigue, helping consumers return to their routines without disruption. By partnering with Rajkummar Rao, Mankind Pharma aims to empower individuals to overcome pain-related challenges and lead pain-free lives.
With Nimulid Strong, Mankind Pharma is poised to take a leading position in the topical pain relief segment. The company’s commitment to innovation, accessibility, and effective pain relief solutions is expected to resonate with consumers, particularly in the digitally driven and fast-paced world of today. As Rajkummar Rao advocates for Nimulid Strong, the brand is likely to reach a wider audience and reinforce its position as a trusted and reliable solution for neck pain and other related issues.
Get to know the sibling duo born on the same day, who are the masterminds behind one of India’s largest pharmaceutical companies, valued at a staggering Rs 97,572 crore.
Mankind Pharma, a leading pharmaceutical company in India, was founded by brothers Ramesh and Rajeev Juneja in 1995 with a modest capital of Rs 50 lakh and just 20 employees. Today, the company is the fourth-largest pharmaceutical company in India, with a market capitalization of Rs 97,572 crore. The Juneja brothers, who hail from Meerut in Uttar Pradesh, have come a long way from their humble beginnings. Ramesh, the chairman and whole-time director, started out as a medical representative, while Rajeev, the vice chairman and managing director, worked in a chemist’s shop.
Despite their simple starts, the brothers had big dreams and a vision to make a mark in the pharmaceutical industry. They launched their operations in just two states in the first year, but over time, their business expanded massively across India and internationally. The company is known for its popular brands such as Manforce condoms, Gas-O-Fast antacid, and the multivitamin HealthOK, all of which were named by Ramesh Juneja.
In April 2023, Mankind Pharma launched its initial public offering (IPO), which attracted significant attention from investors and the public. Two major private equity firms, Capital International and ChrysCapital, have invested in the company, demonstrating their confidence in its potential. The Juneja brothers’ success has also been recognized by Forbes, which estimates Ramesh’s net worth at Rs 27,472 crore and Rajeev’s at Rs 26,613.5 crore.
The journey of Mankind Pharma and the Juneja brothers is an inspiring tale of entrepreneurship and perseverance. From a small business in Meerut to becoming industry giants, their story is a testament to the power of vision, hard work, and innovative thinking. Today, Mankind Pharma is a household name in India, and its products are trusted by millions of people. The company’s success has also created employment opportunities and contributed to the growth of the Indian economy. As Mankind Pharma continues to expand and innovate, its founders remain committed to their mission of providing quality healthcare products to people across the country.
Mankind Pharma appoints Dapinder Singh Narula as new Head of Talent Management, reports People Matters.
Dapinder Singh Narula has been appointed to lead the Talent Management function at Mankind Pharma, a leading Indian pharmaceutical company. In this exclusive interview with People Matters, Narula shared his vision and strategies for talent management in the organization.
With over 15 years of experience in HR, Narula has previously worked with companies like Ranbaxy, Pfizer, and Dr. Reddy’s Laboratories. He has a strong background in talent management, organizational development, and leadership development. At Mankind Pharma, Narula will be responsible for designing and implementing strategies to attract, retain, and develop talent across the organization.
Narula emphasized the importance of talent management in driving business growth and success. He stated that the pharmaceutical industry is highly competitive, and having the right talent is crucial to staying ahead of the curve. He plans to focus on creating a talent pipeline that is aligned with the organization’s business strategy and goals.
To achieve this, Narula will be working on several initiatives, including developing a comprehensive talent management framework, creating a leadership development program, and implementing a performance management system. He will also be focusing on building a strong employer brand to attract top talent to the organization.
Narula also highlighted the importance of digitalization in talent management. He believes that technology can play a key role in enhancing the employee experience, streamlining processes, and providing insights to inform talent decisions. He plans to leverage digital platforms to create a more engaging and personalized experience for employees.
Narula’s appointment is seen as a significant move by Mankind Pharma to prioritize talent management and invest in its people. The company has been growing rapidly, and having the right talent in place will be critical to its continued success. With Narula at the helm of talent management, Mankind Pharma is well-positioned to attract, retain, and develop the talent it needs to drive business growth and stay competitive in the industry.
Overall, Narula’s vision for talent management at Mankind Pharma is focused on creating a strategic approach to talent acquisition, development, and retention. By leveraging technology, building a strong employer brand, and creating a comprehensive talent management framework, Narula aims to drive business success and establish Mankind Pharma as a leader in the pharmaceutical industry.
Delhi High Court allows Mankind Prime Labs to proceed with registering its CROSSRELIEF trademark.
The High Court of Delhi has allowed an appeal by Mankind Prime Labs, directing the Registrar of Trade Marks to process the company’s application for registration of the wordmark “CROSSRELIEF” under Class 5, which pertains to pharmaceutical and medicinal products. The application was initially rejected by the Trade Marks Registry, citing that the mark was similar to earlier marks and likely to cause confusion among the public. However, the Court rejected this rationale, clarifying that the mark “CROSSRELIEF” is a coined term that cannot be dissected or read in parts.
The Court observed that the mark is a composite singular mark that has to be taken as a whole, and it is an arbitrary and fanciful term coined by the appellant. The Court quoted precedent, noting that invented words are entitled to be registered as trademarks, and that a mark cannot be dissected into its individual parts while examining its entitlement to registration. The Court also emphasized that the term “CROSS” is generic in the medical industry and cannot be claimed as a monopoly.
The Court held that the mark “CROSSRELIEF”, when viewed as a whole, is phonetically, visually, and structurally distinct from previously cited marks, and that there is hardly any cause for it to create confusion among the members of the trade or the general public. The Court allowed the appeal and set aside the impugned order, directing the Registrar of Trade Marks to process the application for registration.
However, the Court clarified that the registration of the composite mark “CROSSRELIEF” shall not confer any exclusive right over any individual component or part of the mark, such as “CROSS” or “RELIEF”, upon the appellant. The judgment has been directed to be sent to the Registrar of Trade Marks for compliance. This decision is significant as it highlights the importance of considering a trademark as a whole, rather than dissecting it into its individual parts, and recognizes the generic nature of certain terms in the medical industry.
The Delhi High Court has upheld the KIND brand and quashed the KINDPAN trademark, confirming Mankind’s right to the original.
The Delhi High Court has upheld the KIND brand owned by Mankind Pharma, a leading pharmaceutical company in India, and quashed the opposition to its trademark KINDPAN. This decision has significant implications for the pharmaceutical industry and intellectual property (IP) law in India.
Mankind Pharma had filed for the trademark KINDPAN in 2019, but it was opposed by a rival company, Otsuka Pharmaceutical Company, which claimed that the trademark was similar to its own brand name “Kindly” and could cause confusion among consumers. Otsuka also argued that Mankind Pharma’s application was not in good faith and was an attempt to capitalise on the reputation of Otsuka’s brand.
However, the Delhi High Court has dismissed Otsuka’s opposition and upheld Mankind Pharma’s trademark application. The court observed that the trademarks KINDPAN and Kindly are distinct and the similarity between the two marks is limited only to the prefix “Kind”, which is a common prefix in several trademarks. The court also noted that Mankind Pharma had filed for the trademark KINDPAN in good faith and had not attempted to deceive or mislead consumers.
This judgment is significant for several reasons. Firstly, it establishes that a company can own multiple trademarks with similar prefixes, provided that the marks are distinct and do not cause confusion among consumers. Secondly, it shows that a company’s reputation and goodwill are not transferable to another company, and that each trademark application must be evaluated on its own merit.
The judgment also highlights the importance of clear and precise language in trademark applications. The Delhi High Court emphasized that the similarity between the trademarks KINDPAN and Kindly was limited to the prefix “Kind” and that the marks were not so similar as to cause confusion among consumers.
Overall, this judgment is a positive development for the pharmaceutical industry and IP law in India. It provides a clear framework for trademark applications and oppositions, and helps to ensure that companies can protect their intellectual property rights without undue interference from rival companies.
Delhi High Court Directs Registry to Remove ‘Kindpan’ Trademark Registration.
The Delhi High Court has ruled in favor of Mankind Pharma Limited, ordering the removal of a similar trademark “Kindpan” registered by a proprietorship firm, Sanavita Medicare. Mankind Pharma claimed that it was the owner of the “Kind” and “Mankind” marks, and that the respondent’s registration of the “Kind” mark in class 5 for medicinal and pharmaceutical preparations was an attempt to capitalize on Mankind Pharma’s goodwill and reputation.
The court agreed with Mankind Pharma’s argument, noting that Mankind Pharma was the owner and prior user of the “Kind” and “Mankind” marks, and that the respondent had no plausible reason for adopting the impugned mark. The court observed that the respondent’s application for registration of the impugned mark on a “proposed to be used” basis was suspicious, and that the only reason for doing so was to exploit Mankind Pharma’s established goodwill and built-up reputation.
The court also noted that Mankind Pharma had developed a strong reputation and goodwill in the “Mankind” and “Kind” family of marks, and that the impugned mark was likely to cause confusion among customers. Therefore, the court directed the Trademarks Registry to remove the impugned trademark, citing that it was liable to be taken off due to its similarity to Mankind Pharma’s existing marks.
This decision serves as a reminder of the importance of trademark protection and the need for businesses to vigilantly monitor and protect their intellectual property rights. It also highlights the court’s willingness to take action against trademark infringement and to protect the interests of established businesses.
Launchpad for Wellness: HealthOK Unveils Innovative 100% Vegetarian Multivitamin Range, Backed by Archana Puran Singh
Mankind Pharma, India’s fourth-largest pharmaceutical company, has launched a new campaign for its HealthOK 100% vegetarian multivitamin tablets, featuring actress Archana Puran Singh. The campaign is aimed at raising awareness about the brand’s 100% vegetarian multivitamin tablets, which provide complete nutritional support while aligning with Indian vegetarian’s dietary practices. The campaign humorously depicts Archana’s quest to find a non-vegetarian multivitamin in an Indian vegetarian family function, highlighting the gap between the need for multivitamins and the lack of vegetarian options.
India has a significant vegetarian population, particularly in states like Rajasthan, Uttar Pradesh, Maharashtra, Gujarat, and Delhi NCR, where many follow a strict vegetarian diet. However, many vegetarians unknowingly consume non-vegetarian multivitamin supplements, which conflicts with their lifestyle. HealthOK tablets address this concern by offering 100% vegetarian multivitamin tablets, enriched with Taurine and Ginseng, providing essential nutrients without compromising on dietary preferences.
The campaign, which will be launched across various platforms, coincides with the Navratri festivities, a time when many Indians embrace vegetarianism as part of their religious observance. Archana Puran Singh, who is a strict vegetarian herself, has expressed her enthusiasm about the campaign, stating that it is crucial for vegetarians to be aware of the HealthOK vegetarian nutritional supplement being available, which they can consume. The campaign aims to create strong awareness about HealthOK as the preferred choice for vegetarians seeking a high-quality multivitamin solution.
Mankind Pharma’s debt instruments lose credit rating CARE
Mankind Pharma is an Indian pharmaceutical company that develops, manufactures, and markets a diverse range of pharmaceutical formulations and consumer healthcare products. The company’s portfolio includes a broad spectrum of treatments for various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neurology, vitamins, minerals, and respiratory health.
The company’s product range is vast, with over 200 products, including prescription and over-the-counter (OTC) branded products. Its portfolio of brands covers women’s health, fertility, and critical care, with multiple brands present in each therapy area. Some of its notable brands include Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, and Dynaglipt, among others.
Mankind Pharma has a strong presence in the Indian market, with several subsidiaries, including Lifestar Pharma Private Limited, Magnet Labs Private Limited, and Jaspack Industries Private Limited, to name a few. The company’s portfolio is constantly evolving, with a focus on innovation, quality, and reliability, to provide effective and affordable healthcare solutions to its customers. With a wide range of products and a strong distribution network, Mankind Pharma is a significant player in the Indian pharmaceutical industry.
Mankind Pharma clears hurdle as CDSCO panel approves bioequivalence study for Resmetirom Tablets.
Mankind Pharma, a leading pharmaceutical company in India, has reportedly received approval from the Central Drugs Standard Control Organization (CDSCO) panel for conducting a bioequivalence study of its Resmetirom Tablets. This development is significant for the company as it paves the way for the launch of a generic version of the branded drug in the Indian market.
The bioequivalence study is a critical step in the approval process for generic drugs, which involves comparing the pharmacokinetic and pharmacodynamic properties of the generic product with those of the branded product. The CDSCO panel’s approval indicates that Mankind Pharma’s Resmetirom Tablets have demonstrated comparable bioavailability, pharmacokinetics, and efficacy to the branded drug.
Resmetirom is a marketed branded product for the treatment of certain types of anemia, and its generic version is expected to provide an affordable alternative to patients. The Indian pharmaceutical market, one of the largest in the world, is often referred to as the “pharmacy of the world” due to its large population and significant demand for medicines.
The approval of the bioequivalence study is a testament to Mankind Pharma’s commitment to quality and research, as well as its ability to develop high-quality generic drugs that meet international standards. With this approval, the company can now proceed with the launch of its generic Resmetirom Tablets, which is expected to benefit patients who require this treatment.
The approval also demonstrates the CDSCO’s commitment to fostering a competitive and innovative pharmaceutical industry in India. The organization’s efforts to streamline the approval process and facilitate the development of generic drugs are expected to lead to increased access to affordable medicines for patients in India and other countries.
Overall, the approval of the bioequivalence study for Mankind Pharma’s Resmetirom Tablets is a significant development in the Indian pharmaceutical industry, marking a step towards making high-quality generic drugs more accessible to patients. With its commitment to research and development, Mankind Pharma is well-positioned to continue making a positive impact on the healthcare landscape in India and beyond.
Eli Lilly expands its global footprint by introducing Mounjaro, a groundbreaking weight management medication, to the Indian market.
Eli Lilly & Co. has launched its anti-obesity drug Mounjaro in India, making it the country’s first treatment of its kind. The drug, which is used to treat obesity and type-2 diabetes, works by activating hormones that help reduce the amount of sugar in the blood and slow digestion. Mounjaro is priced at ₹3,500 to ₹4,375 per month, depending on the dosage.
The company has faced competition from other foreign pharma companies, with plans to introduce similar products in the growing market. However, Mounjaro’s unique pricing strategy, which is expected to be around 14,000-17,500 per month, makes it an attractive option for Indian patients.
The demand for GLP-1 drugs, which help reduce weight, has boomed, with the market expected to reach $100 billion by 2030. However, rival semaglutide (Ozempic) goes off-patent in 2026, and generics makers like Cipla, Dr Reddy’s, Lupin, Natco Pharma, Mankind Pharma, and Biocon are gearing up to launch cheaper generic copies.
Despite this, experts expect Mounjaro to be a hit in India, given the high demand for weight loss drugs. According to a senior diabetologist, a significant percentage of his patients are overweight, and the use of Mounjaro could lead to a 15-20% pickup in patients with type-2 diabetes.
In addition, the growing number of people with obesity in India, from 180 million in 2021 to 450 million by 2050, could lead to increased demand for weight loss drugs like Mounjaro. The market for GLP-1 drugs for patients with diabetes in India has already doubled to $3.6 billion in 2024, driven by unauthorized use of drugs like Ozempic and Mounjaro through the grey market.
India sees a significant decrease in the price of a commonly used diabetes medication following the introduction of generic alternatives.
The price of the diabetes drug empagliflozin, also known as Jardiance, has been significantly reduced by almost one-tenth in India. The drug, developed by German pharma giant Boehringer Ingelheim, is used to control blood sugar levels in patients with type 2 diabetes. The original price of the drug was around Rs 60 per tablet, but with the entry of its generic versions in the market, it is now available for as low as Rs 5.5 per tablet.
Mankind, Alkem, and Glenmark Pharmaceuticals have launched generic versions of empagliflozin, with prices starting from Rs 5.49 per tablet for the 10 mg variant. These prices are nearly 80% lower than the original price of the innovator product. The generic versions of the drug come with additional features, such as anti-counterfeit security bands, patient education information, and QR codes that provide prescribing information and additional patient education.
The launch of these generic versions of empagliflozin is a significant step in making the drug more affordable for millions of Indians who are suffering from type 2 diabetes. India is known as the diabetes capital of the world, with over 10 crore people diagnosed with the disease, according to the Indian Council of Medical Research–India Diabetes (ICMR INDIAB) study in 2023. Reducing the cost of anti-diabetes medicines like empagliflozin is a crucial step in tackling the disease burden in the country.
This popular diabetes medication is set to get a significant price cut, dropping from Rs 60 to just Rs 9 per unit.
The cost of Empagliflozin, a crucial drug for managing diabetes and its associated conditions, is set to drop significantly in India. The price of the medicine, which was previously around Rs 60 per tablet, will be reduced to just Rs 9 per tablet, making it more accessible to millions of diabetes patients in the country. This development comes after the patent for the drug, which was previously held by German pharmaceutical company Boehringer Ingelheim, expired on March 11.
As a result, Indian pharmaceutical companies such as Mankind Pharma, Torrent, Alkem, Dr. Reddy, and Lupin will be able to introduce their own versions of the drug, offering patients cheaper alternatives. Mankind Pharma, for example, plans to offer the drug at a price 90% lower than the innovator company, making it more affordable for patients.
Empagliflozin plays a crucial role in preventing heart failure and delaying kidney failure, making it a vital medication for those with diabetes. However, its high cost has previously made it difficult for many to access. The introduction of more affordable options from Indian companies is expected to bring significant benefits to millions of patients.
The reduced price of Empagliflozin is poised to provide much-needed financial relief to diabetes patients, who often face the burden of out-of-pocket medication expenses. In India, over 10.1 crore people are living with diabetes, and limited insurance coverage often leaves patients to shoulder medication costs independently. The availability of more affordable options is expected to make a significant difference in the lives of these patients.
The economic burden of diabetes in India is substantial, and the reduced price of Empagliflozin is a welcome development for diabetic patients across the country. With the introduction of more affordable alternatives, millions of patients will have access to a vital medication, allowing them to better manage their condition and improve their overall health.